分泌性癌是一种恶性唾液腺肿瘤，最初于 2010 年描述。这种罕见的肿瘤与 t(12;15) (p13;q25) 易位相关，产生融合基因 ETV6-NTRK3。由于这种肿瘤相当罕见，因此大多数出版物仅描述了一小部分患者。我们旨在研究这种新定义的恶性实体的临床、病理和预后特征。Pubmed、Google Scholar 和 Web of Science 数据库。对 2010 年至 2023 年期间发表的所有文章进行了回顾。搜索术语包括术语“乳腺类似分泌性癌”和“分泌性癌”。检索所有以英文发表的有关唾液腺分泌性癌的文章。共纳入1012篇回顾性文章，共报告674例患者，其中男性52%，平均年龄44.9±18.9岁。就诊时晚期疾病（3/4 期）患者的事件发生率为 24.1%（95% CI 17.6%-31.9%，I2 = 9.2%），区域转移为 14.6%（95% CI 10.5%-20） %，I2 = 12%），远处转移事件率为8.4%（95% CI 5.5%-12.7%，I2 = 4.2%）。 30.3%的患者接受了辅助放疗（95% CI 24.1%-37.2%，I2 = 21.5%）。复发率为19%（95% CI 15.1%-23.8%，I2 = 5%）。生存结果显示，分泌性癌患者的疾病死亡率为 17.2%（95% CI 13.5%-21.8%，I2 = 7.3%）。分泌性癌是一种罕见且相对新定义的实体，最常见于腮腺。其特点为低级别肿瘤，大多数患者诊断时处于早期阶段，无局部或远处病变，预后相对较好。N/A 喉镜，2023。© 2023 作者。 《喉镜》由 Wiley periodicals LLC 代表美国喉科、鼻科和耳科协会出版。

Secretory Carcinoma is a malignant salivary gland tumor, initially described in 2010. This rare tumor is associated with the translocation t(12;15) (p13;q25), resulting in the fusion gene ETV6-NTRK3. Since this tumor is quite rare, most publications describe only small cohorts of patients. We aimed to investigate the clinical, pathological, and prognostic features of this newly defined malignant entity.Pubmed, Google Scholar, and Web of Science databases.All published articles between 2010 and 2023 were reviewed. Search terms included the terms "Mammary Analogue Secretory Carcinoma" and "Secretory Carcinoma". All articles published in English reporting on Secretory Carcinoma of salivary glands were retrieved.One-hundred and 12 retrospective articles reporting a total of 674 patients were included, with 52% males and a mean age of 44.9 ± 18.9. The event rate for patients with advanced-stage disease (Stage 3/4) at presentation was 24.1% (95% CI 17.6%-31.9%, I2  = 9.2%), 14.6% for regional metastases (95% CI 10.5%-20%, I2  = 12%), and the event rate of distant metastasis was 8.4% (95% CI 5.5%-12.7%, I2  = 4.2%). Adjuvant radiotherapy was administered for 30.3% of patients (95% CI 24.1%-37.2%, I2  = 21.5%). The recurrence rate was 19% (95% CI 15.1%-23.8%, I2  = 5%). Survival outcomes showed a 17.2% death of disease rate for Secretory Carcinoma patients (95% CI 13.5%-21.8%, I2  = 7.3%).Secretory Carcinoma is a rare and relatively newly defined entity arising in the parotid gland most commonly. Characterized as a low-grade tumor, the majority of patients are diagnosed at an early stage, without regional or distant disease, and the prognosis is relatively good.N/A Laryngoscope, 2023.© 2023 The Authors. The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.